EC 691-567-9
Also known as CPT-11 and Camptosar.
Phase 3 G‑HOPE‑001 met dual endpoints in CLDN18.2‑positive advanced G/GEJA—median OS 10.2 vs 6.9 months and PFS 7.1 vs 3.1 months versus physician’s choice.
